Bactiguard Holding AB (publ) (BACTI-B) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.024x

Based on the latest financial reports, Bactiguard Holding AB (publ) (BACTI-B) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.43 Million ≈ $-799.91K USD) by net assets (Skr311.60 Million ≈ $33.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BACTI-B stock market capitalisation for the company's overall valuation and market capitalisation.

Bactiguard Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Bactiguard Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Bactiguard Holding AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bactiguard Holding AB (publ) ranked by their cash flow conversion efficiency. Explore Bactiguard Holding AB (publ) cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Bokwang Industry Co Ltd
KQ:225530
0.002x
Urja Global Limited
NSE:URJA
-0.086x
New Century Logistics (BVI) Limited Ordinary Shares
NASDAQ:NCEW
0.782x
HLB Global Co Ltd
KO:003580
-0.045x
Harmoney Corp Ltd
AU:HMY
0.514x
Dreadnought Resources Ltd
AU:DRE
-0.014x
Zee Media Corporation Limited
NSE:ZEEMEDIA
0.290x
Osmanli Menkul Degerler AS
IS:OSMEN
-0.129x

Annual Cash Flow Conversion Efficiency for Bactiguard Holding AB (publ) (2009–2025)

The table below shows the annual cash flow conversion efficiency of Bactiguard Holding AB (publ) from 2009 to 2025. View Bactiguard Holding AB (publ) (BACTI-B) share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr314.93 Million
≈ $33.89 Million
Skr-1.49 Million
≈ $-160.02K
-0.005x -106.20%
2024-12-31 Skr328.34 Million
≈ $35.33 Million
Skr24.99 Million
≈ $2.69 Million
0.076x +151.36%
2023-12-31 Skr353.18 Million
≈ $38.01 Million
Skr-52.33 Million
≈ $-5.63 Million
-0.148x -2498.76%
2022-12-31 Skr495.71 Million
≈ $53.35 Million
Skr3.06 Million
≈ $329.52K
0.006x -53.91%
2021-12-31 Skr541.45 Million
≈ $58.27 Million
Skr7.26 Million
≈ $780.86K
0.013x +612.72%
2020-12-31 Skr373.35 Million
≈ $40.18 Million
Skr702.00K
≈ $75.55K
0.002x -98.65%
2019-12-31 Skr386.69 Million
≈ $41.61 Million
Skr53.98 Million
≈ $5.81 Million
0.140x +410.15%
2018-12-31 Skr370.82 Million
≈ $39.91 Million
Skr-16.69 Million
≈ $-1.80 Million
-0.045x -384.84%
2017-12-31 Skr387.11 Million
≈ $41.66 Million
Skr6.12 Million
≈ $658.29K
0.016x +149.70%
2016-12-31 Skr390.33 Million
≈ $42.01 Million
Skr-12.41 Million
≈ $-1.34 Million
-0.032x +36.16%
2015-12-31 Skr417.44 Million
≈ $44.92 Million
Skr-20.79 Million
≈ $-2.24 Million
-0.050x +27.72%
2014-12-31 Skr518.71 Million
≈ $55.82 Million
Skr-35.74 Million
≈ $-3.85 Million
-0.069x +78.45%
2013-12-31 Skr140.95 Million
≈ $15.17 Million
Skr-45.07 Million
≈ $-4.85 Million
-0.320x -13.00%
2012-12-31 Skr144.60 Million
≈ $15.56 Million
Skr-40.92 Million
≈ $-4.40 Million
-0.283x -1883.43%
2011-12-31 Skr187.86 Million
≈ $20.22 Million
Skr-2.68 Million
≈ $-288.41K
-0.014x -107.36%
2010-12-31 Skr292.61 Million
≈ $31.49 Million
Skr56.71 Million
≈ $6.10 Million
0.194x -22.88%
2009-12-31 Skr317.39 Million
≈ $34.16 Million
Skr79.76 Million
≈ $8.58 Million
0.251x --

About Bactiguard Holding AB (publ)

ST:BACTI-B Sweden Medical Devices
Market Cap
$51.95 Million
Skr482.73 Million SEK
Market Cap Rank
#21857 Global
#403 in Sweden
Share Price
Skr15.55
Change (1 day)
+0.32%
52-Week Range
Skr14.10 - Skr22.90
All Time High
Skr205.00
About

Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management … Read more